The Role of CHD1 Loss on Cistrome Reprogramming and Prostate Cancer ProgressionCBChristopher BarbieriProstate Cancer Foundation · 2017–2021PCF 17091418-01
Development and Qualification of the PCF SELECT (Specific Evaluation in Liquid Biopsies of Established Prostate Cancer Targets) Plasma DNA AssayHBHimisha BeltranProstate Cancer Foundation · 2016–201816CHAL01
Targeting Fc gamma receptors (FcɣRs) with stereotactic radiation to reprogram myeloid-derived immune cells in the prostate tumor microenvironmentAEAriel E. MarciscanoProstate Cancer Foundation · 2021–2024PCF 20YOUN09
Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic CancerDMDavid M NanusPGParaskevi GiannakakouSTScott T. TagawaProstate Cancer Foundation · 2014–2020 · via Duke UniversityDU 14111569-01
Cost-Effectiveness of Prostate Cancer Screening in the United States: Evaluating Current Practice and Emerging StrategiesJCJim C. HuKKKevin KenslerProstate Cancer Foundation · 2026–202925PILO02Active
MBD4-Driven AR Reprogramming and Luminal Lineage Specification in Prostate CancerXCXuanrong ChenProstate Cancer Foundation · 2025–2028PCF 255836-01Active
Prostate Cancer Foundation subaward for Janny Villa PulgarinCBChristopher BarbieriJVJanny Villa PulgarinProstate Cancer Foundation · 2023–2027 · via The General Hospital Corporation (dba Massachusetts General Hospital)PCF 20YOUN09Ending soon
Targeting BRN2 in Neuroendocrine Prostate CancerHBHimisha BeltranProstate Cancer Foundation · 2017–201817CHAL13
Defining Evolution of Prostate Cancer Metastasis Under Therapeutic Pressure Using Recordable BarcodeLBLise BraultDNDawid NowakProstate Cancer Foundation · 2025–202825YOUN26Active
Development and optimization of CEACAM5-targeted alpha emittersSTScott T. TagawaDSDavid S. RickmanEKEdward K FungJKJames Kelly+3 moreProstate Cancer Foundation · 2025–202724CHAL11Ending soon
Targeting Genomic Instability in SPOP Mutant Prostate Cancer.CBChristopher BarbieriProstate Cancer Foundation · 2014–2017PCF 15060870-03 EWOF
Targeting lipid metabolism and diet in patients with locally advanced prostate cancerMLMassimo LodaCBChristopher BarbieriDMDavid M NanusJKJames KellyProstate Cancer Foundation · 2023–2023PCF 227920-01
Early Detection of Neuroendocrine Prostate Cancer Transformation Using Circulatin Genomic SignaturesHBHimisha BeltranPJPaul J ChristosProstate Cancer Foundation · 2014–2018PCF 15111792-02
Optimization of Prostate-Specific Membrane Antigen-Targeted RadiationSTScott T. TagawaFKFrancesca KhaniHBHimisha BeltranJRJoseph Reginald Osborne+2 moreProstate Cancer Foundation · 2017–202717CHAL11Ending soon
Predicting off-target resistance to androgen receptor signaling inhibitors from histology slides using foundation modelsEKEkta KhuranaBDBrian D. RobinsonIHIman HajirasoulihaProstate Cancer Foundation · 2026–2028PCF 252114-01Active
The impacts of RNA-based classifiers on prostate cancer prognosisASAndrea SbonerProstate Cancer Foundation · 2019–2021PCF 19YOUN15
Metabolic and Inflammatory Response to a Whole Food Plant-Based Diet in Overweight/Obese Men with Prostate Cancer Receiving Androgen Deprivation Therapy: A Phase II Randomized StudyDMDavid M NanusJKJan KrumsiekProstate Cancer Foundation · 2022–202721CHAL08Ending soon
Assessing the Impact of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Advanced Prostate Cancer Risk and OutcomesKKKevin KenslerProstate Cancer Foundation · 2025–202825YOUN29Active
Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug ConjugateSTScott T. TagawaProstate Cancer Foundation · 2017–2024 · via University of Wisconsin17CHAL05